Nebulizer meds paid, just not on fee schedule

Why This Topic Matters

Healthcare practices that administer these medications in the office need to know how Medicare payment policy affects claim submission and reimbursement. The article helps readers understand the broader billing context and the importance of using the current HCPCS reporting approach for Medicare Part B drugs.

Article Sections

1. Medicare payment update for nebulizer drugs

   Introduces a Medicare policy update affecting office-administered respiratory medications and explains the general payment context. The section frames the issue for practices that report these drugs under Medicare Part B.

2. Coding history and quarterly update context

   Summarizes earlier coding changes and the sequence of revisions leading up to the current reporting approach. This section provides background on how the guidance evolved over time.

3. CMS clarification on payment source

   Describes the CMS clarification about how Medicare processes payment for these drugs and where reimbursement is drawn from. The discussion centers on the program structure rather than detailed billing tactics.

4. Coding quick tip: Albuterol and levalbuterol

   Presents a concise reference to the relevant HCPCS reporting items and the date-of-service context for their use. It serves as a quick review of the medication coding update.